Molecular markers of prostate cancer (Q36669988)

15 August 2017

1 reference

title

Molecular markers of prostate cancer (English)

1 reference

15 August 2017

1 reference

Timothy J Bradford

1

1 reference

15 August 2017

Scott A Tomlins

series ordinal

2

1 reference

15 August 2017

Xiaoju Wang

series ordinal

3

1 reference

15 August 2017

Arul M Chinnaiyan

series ordinal

4

1 reference

15 August 2017

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

24

1 reference

15 August 2017

6

1 reference

15 August 2017

538-551

1 reference

15 August 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Precipitating antigens of the normal human prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate cancer incidence and mortality rates and trends in the United States and Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

American Cancer Society Guidelines for the Early Detection of Cancer, 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Screening for prostate cancer with prostate-specific antigen: beware the biases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Usefulness of the (F/T)/PSA density ratio to detect prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

A catalog of prostate cancer nomograms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

20-year outcomes following conservative management of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Natural History of Early, Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Radical prostatectomy versus watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Expression analysis of ?-catenin and prostate-specific membrane antigen: Their potential as diagnostic markers for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Follow-up evaluation of a phase II prostate cancer vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate stem cell antigen is overexpressed in prostate cancer metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Anti–Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell DeathIn vitroand Inhibits Tumor GrowthIn vivovia a Fc-Independent Mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Detection of prostate cancer and predicting progression: current and future diagnostic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Early identification of individuals with prostate cancer in negative biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Delineation of prognostic biomarkers in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The polycomb group protein EZH2 is involved in progression of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Primary structure of a human glandular kallikrein gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Testing in Serum for Human Glandular Kallikrein 2, and Free and Total Prostate Specific Antigen in Biannual Screening for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

[Improving the specificity of PSA's in the diagnostic gray zone 4-10 ng/ml by human glandular kallikrein]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Transforming growth factor beta as a clinical biomarker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Interleukin-6 is an autocrine growth factor in human prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Interleukin-6 polymorphism is associated with more aggressive prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum interleukin-8 is elevated in men with prostate cancer and bone metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Neuroendocrine differentiation in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The chromogranin-A (CgA) in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Circulating neuroendocrine markers in patients with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum chromogranin-A in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

P504S: a new molecular marker for the detection of prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

In mouse alpha -methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Purification and characterization of an alpha-methylacyl-CoA racemase from human liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The 8;21 translocation in leukemogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Fingerprinting the circulating repertoire of antibodies from cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Human neoplasms elicit multiple specific immune responses in the autologous host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Immune response as a biomarker for cancer detection and a lot more

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Autoantibodies to prostasomes as new markers for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Autoantibody signatures in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Revealing urologic diseases by proteomic techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Cancer proteomics: Serum diagnostics for tumor marker discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum proteomic patterns for detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Diagnostic potential of serum proteomic patterns in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate carcinoma tissue proteomics for biomarker discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Use of thymosin beta15 as a urinary biomarker in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Abnormal expression of MDM2 in prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

High expression of a new marker PCA-1 in human prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

DNA-based detection of prostate cancer in blood, urine, and ejaculates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

DNA-based detection of prostate cancer in urine after prostatic massage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

uPM3, a new molecular urine test for the detection of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8?16

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Use of multiple biomarkers for a molecular diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

The human plasma proteome: history, character, and diagnostic prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

Transforming growth factor β1 as a biomarker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Interleukin-6 in biology and medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2006.07.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLONC.2006.07.004

1 reference

15 August 2017

1 reference